{"nctId":"NCT01664247","briefTitle":"The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification","startDateStruct":{"date":"2012-10-01","type":"ACTUAL"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"count":346,"armGroups":[{"label":"IDeg + Lira","type":"EXPERIMENTAL","interventionNames":["Drug: insulin degludec","Drug: liraglutide"]},{"label":"Placebo + Lira","type":"EXPERIMENTAL","interventionNames":["Drug: placebo","Drug: liraglutide"]}],"interventions":[{"name":"insulin degludec","otherNames":[]},{"name":"placebo","otherNames":[]},{"name":"liraglutide","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 diabetes\n* Insulin naïve\n* Ongoing treatment with metformin or metformin in combination with either sulphonylurea (SU), glinides, dipeptidyl peptidase-IV (DPP-IV) inhibitors or exenatide (only twice daily (BID))\n* Glycosylated haemoglobin (HbA1c) (by central laboratory analysis): a. 7.5-10.0 % (both inclusive) for subjects on metformin monotherapy, b. 7.0-9.0 % (both inclusive) for subjects on metformin in combination with either SU, glinides, DPP-IV inhibitors or exenatide (only BID)\n\nExclusion Criteria:\n\n* Treatment with glucose-lowering agent(s) other than stated in the inclusion criteria within 12 weeks\n* Calcitonin equal to or above 50 pg/mL\n* Stroke; heart failure New York Heart Association (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty; all within 24 weeks\n* Current or past (within the last 5 years) malignant neoplasms (except basal cell and squamous cell carcinoma)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%)","description":"Change from baseline in HbA1c after 26 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.99","spread":"0.08"},{"groupId":"OG001","value":"-0.07","spread":"0.08"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG)","description":"Change from baseline in FPG after 26 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.60","spread":"2.91"},{"groupId":"OG001","value":"-0.28","spread":"2.44"}]}]}]},{"type":"SECONDARY","title":"Number of Responders for HbA1c (Below 7.0 %)","description":"Number of responders for HbA1c below 7.0%, after 26 weeks of randomised treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.6","spread":null},{"groupId":"OG001","value":"35.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean Pre-breakfast Measurements Used for Titration","description":"Change from baseline after 26 weeks of treatment in the average of the pre-breakfast self measured plasma glucose (SMPG) measured on the day of the contact and the two days immediately prior to the contact. The least squares means presented are the estimated values after 26 weeks of treatment and the statistical analysis presents the treatment difference of the change from baseline values as the model is adjusted for baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.88","spread":"0.14"},{"groupId":"OG001","value":"8.23","spread":"0.15"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 8-point Profile","description":"The change from baseline in the 8-point SMPG profile after 26 weeks of randomised treatment. The least squares means presented are the estimated values after 26 weeks of treatment and the statistical analysis presents the treatment difference of the change from baseline values as the model is adjusted for baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.85","spread":"0.15"},{"groupId":"OG001","value":"8.54","spread":"0.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.65","spread":"0.24"},{"groupId":"OG001","value":"9.75","spread":"0.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.33","spread":"0.18"},{"groupId":"OG001","value":"8.34","spread":"0.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.73","spread":"0.21"},{"groupId":"OG001","value":"9.67","spread":"0.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.77","spread":"0.20"},{"groupId":"OG001","value":"9.51","spread":"0.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.93","spread":"0.21"},{"groupId":"OG001","value":"9.65","spread":"0.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.21","spread":"0.20"},{"groupId":"OG001","value":"8.95","spread":"0.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.05","spread":"0.17"},{"groupId":"OG001","value":"8.55","spread":"0.18"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean of the 8-point Profile","description":"Change from baseline in mean of the 8-point profile after 26 weeks of randomised treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"1.8"},{"groupId":"OG001","value":"-0.5","spread":"1.7"}]}]}]},{"type":"SECONDARY","title":"Number of Hypoglycaemic Episodes","description":"Number of confirmed hypoglycaemic episodes from week 0 to 26 weeks of randomised treatment. A hypoglycaemic episode was defined as treatment emergent if the onset of the episode occurred after the first administration of investigational medicinal product and no later than 7 days after the last day on trial product. Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia or minor hypoglycaemic episodes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Adverse Events","description":"Number of treatment emergent AEs (TEAEs) from week 0 to week 26 of the randomised treatment. A TEAE was defined as an event that had onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"285","spread":null},{"groupId":"OG001","value":"252","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient Reported Health-related Quality of Life Using the Short-Form 36 Health Survey Version 2 (SF-36®v2)","description":"Change in subject's quality of life was evaluated using the Short-Form 36 Health Survey version 2 (SF-36®v2). Evaluations were performed at baseline and at the last treatment visit (week 26). SF-36 was assessed on a scale range of 0.65 to 80.73 for physical health and -8.81 to 81.65 for mental health respectively, where higher scores indicated a better quality of life. 0-100 scores from the SF-36 were converted to a norm-based score using a T-score transformation in order to obtain a direct interpretation in relation to the distribution of the scores in the 1998 U.S. general population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"6.3"},{"groupId":"OG001","value":"0.0","spread":"6.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"8.1"},{"groupId":"OG001","value":"-0.7","spread":"8.8"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":173},"commonTop":["Nasopharyngitis","Diarrhoea","Lipase increased"]}}}